Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management
January 22 2021 - 4:49PM
Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company
developing next-generation vaccines for serious infectious
diseases, today announced the appointment of Madelyn ‘Lyn’
Caltabiano, Ph.D. to the position of Senior Vice President, Global
Program Management. In this newly created role, Dr. Caltabiano will
lead and expand the Global Program Management organization for the
company’s pipeline and will develop appropriate strategies to
assess the company’s operational performance, including areas
related to portfolio valuation, milestone decision making and
prioritization. She will report directly to Stanley C. Erck,
President and Chief Executive Officer.
“Lyn’s deep experience in managing complex
global programs will be critical as we work to simultaneously
advance NVX-CoV2373 regulatory activities forward in multiple
regions,” said Mr. Erck. “We welcome her invaluable project
management experience as Novavax works to effectively deliver our
vaccine candidate in the fight against the COVID-19 pandemic.”
Dr. Caltabiano joins Novavax from NexEos
Diagnostics, Inc., where she was Development Lead and a core member
of the management team. Previously, as Senior Vice President,
Global Project and Alliance Management at Merck Research
Laboratories, she rebuilt the R&D project and Alliance
Management organizations and led the development of critical
portfolio management and executive decision-making processes.
Earlier, Dr. Caltabiano spent more than a decade at GlaxoSmithKline
where she built the Alliance Management organization, headed
project operations in Oncology R&D, and led the development of
several new therapeutics.
Dr. Caltabiano graduated summa cum laude from
Drexel University with a Bachelor of Science in biological sciences
and earned a doctorate in pathology from the University of
Pennsylvania.
About NVX-CoV2373NVX-CoV2373 is
a protein-based vaccine candidate engineered from the genetic
sequence of SARS-CoV-2, the virus that causes COVID-19 disease.
NVX-CoV2373 was created using Novavax’ recombinant nanoparticle
technology to generate antigen derived from the coronavirus spike
(S) protein. It is adjuvanted with Novavax’ patented saponin-based
Matrix-M™ to enhance the immune response and stimulate high levels
of neutralizing antibodies. NVX-CoV2373 contains purified protein
antigen and can neither replicate, nor can it cause COVID-19. In
preclinical studies, NVX-CoV2373 induced antibodies that block
binding of spike protein to cellular receptors and provided
protection from infection and disease. NVX-CoV2373 was generally
well-tolerated and elicited robust antibody response numerically
superior to that seen in human convalescent sera in Phase 1/2
clinical testing. NVX-CoV2373 is currently being evaluated in two
pivotal Phase 3 trials: a trial in the U.K. that
completed enrollment in November and the PREVENT-19 trial in
the U.S. and Mexico that began in December. It
is also being tested in two ongoing Phase 2 studies that began in
August: a Phase 2b trial in South Africa, and a Phase 1/2
continuation in the U.S. and Australia.
About Matrix-M™Novavax’
patented saponin-based Matrix-M™ adjuvant has demonstrated a potent
and well-tolerated effect by stimulating the entry of antigen
presenting cells into the injection site and enhancing antigen
presentation in local lymph nodes, boosting immune response.
About NovavaxNovavax,
Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that
promotes improved health globally through the discovery,
development and commercialization of innovative vaccines to prevent
serious infectious diseases. The Company’s proprietary recombinant
technology platform combines the power and speed of genetic
engineering to efficiently produce highly immunogenic nanoparticles
designed to address urgent global health needs. Novavax is
conducting late-stage clinical trials for NVX-CoV2373, its vaccine
candidate against SARS-CoV-2, the virus that causes COVID-19.
NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all
primary objectives in its pivotal Phase 3 clinical trial in older
adults and will be advanced for regulatory submission. Both vaccine
candidates incorporate Novavax’ proprietary saponin-based Matrix-M™
adjuvant to enhance the immune response and stimulate high levels
of neutralizing antibodies.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Novavax Forward Looking
StatementsStatements herein relating to the future
of Novavax and the ongoing development of its vaccine and
adjuvant products are forward-looking
statements. Novavax cautions that these forward-looking
statements are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those
expressed or implied by such statements. These risks and
uncertainties include those identified under the heading “Risk
Factors” in the Novavax Annual Report on Form 10-K for the year
ended December 31, 2019, and Quarterly Report on
Form 10-Q for the period ended September 30, 2020,
as filed with the Securities and Exchange
Commission (SEC). We caution investors not to place
considerable reliance on forward-looking statements contained in
this press release. You are encouraged to read our filings with
the SEC, available at sec.gov, for a discussion of these
and other risks and uncertainties. The forward-looking statements
in this press release speak only as of the date of this document,
and we undertake no obligation to update or revise any of the
statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
Contacts:
Investors
Erika Trahan
ir@novavax.com
240-268-2022
Media
Edna Kaplan
media@novavax.com
617-974-8659
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From May 2023 to May 2024